Tuesday 18 June 2024

Global Telemedicine Market: Trends, Opportunities, and Forecast 2024-2030

 


The global Telemedicine Market size is expected to reach USD 380.3 billion by 2030, registering a CAGR of around 18.0% from 2024 to 2030, based on a new report by Grand View Research, Inc. Rising prevalence of chronic illnesses, increased traditional healthcare costs, evolution of mhealth services in healthcare institutions, and a growing number of digital health users attribute to market growth. Favorable government initiatives led to introduction of advanced healthcare IT infrastructure and facilities that fuels growth of the market. For instance, the Research and Innovation Enterprise Plan in Singapore supports digital innovation that focuses on healthcare.

COVID-19 positively impacted the market growth as it increased awareness and adoption rates among patients and healthcare providers, leading to increased investment activities. In response to the pandemic, both state and federal laws in U.S. have been modified to facilitate the widespread use of telemedicine. The Coronavirus Preparedness and Response Supplemental Appropriations Act of March 2020, expanded the reimbursement coverage for telehealth services and provided emergency funding of USD 8.0 billion for federal agencies. Many U.S. states also waived licensure requirements, enabling better utilization of the services. These factors collectively contributed to the market growth during pandemic.

Rapid technological improvements have also increased the demand for online consultation, adding to market growth. In March 2022, Plantronics Inc., renamed as Poly, announced its partnership with Raydiant for making advancements in telemedicine services. The purpose was to optimize remote, hybrid, and in-office team communication for facilitating health communication. The market growth of telehealth products is also expected to be driven by presence of established companies, emerging start-ups and various other initiatives such as mergers, partnerships, and acquisitions. In January 2021, Teladoc, Inc. announced the acquisition of Consultant Connect Limited. Consultant Connect is a UK-based telemedicine provider that facilitates connections and information sharing between healthcare professionals.

List of Key Players in the Telemedicine Market

  • MDlive, Inc. (Evernorth)
  • American Well Corporation
  • Twilio Inc.
  • Teladoc Health, Inc.
  • Doctor On Demand, Inc. (Included Health)
  • Zoom Video Communications, Inc.
  • SOC Telemed, Inc. 
  • NXGN Management, LLC
  • Plantronics, Inc.
  • Practo
  • VSee

Related Press Release@ Telemedicine Market Report

Telemedicine Market Report Highlights

  • The products segment dominated the market in 2023 while services segment is projected to grow with the fastest CAGR of 18.90% over the forecast period from 2024 to 2030.
  • Real-time segment contributed to the largest revenue share in modality segment in 2023. Increasing uptake of on-demand virtual visits and enhanced care delivery over video are anticipated to be the vital drivers for the real time telemedicine solutions market growth
  • Web/mobile-based delivery model is projected to experience substantial growth over the forecast period owing to the widespread adoption of smartphones and internet penetration
  • Based on application, teleradiology dominated the market in 2023. Key growth drivers for this segment include integrating Artificial Intelligence (AI) into teleradiology, implementing a Picture Archiving and Communication System (PACS), and increasing R&D activities in eHealth
  • Based on end-use, patients segment held the dominant share of overall market in 2023, owing to patients using telemedicine services for various health issues, from mild to emergency situations
  • North America has seen a high adoption of telehealth solutions, resulting in its domination of the global market. The region's abundant advanced healthcare facilities and widespread adoption of digital technologies have contributed to its large market share

Request For A Free Consultation@ https://www.grandviewresearch.com/request-free-consultation/193/rfc

Telemedicine Market Segmentation

Grand View Research has segmented the global telemedicine market based on component, modality, application, delivery mode, facility, end-use, and region:

Telemedicine Component Outlook (Revenue, USD Billion, 2018 - 2030)

  • Product
    • Hardware
    • Software
    • Others
  • Services
    • Tele-consulting
    • Tele-monitoring
    • Tele-education

Telemedicine Modality Outlook (Revenue, USD Billion, 2018 - 2030)

  • Store and forward
  • Real time
  • Others

Telemedicine Application Outlook (Revenue, USD Billion, 2018 - 2030)

  • Teleradiology
  • Telepsychiatry
  • Telepathology
  • Teledermatology
  • Telecardiology
  • Others

Telemedicine Delivery Mode Outlook (Revenue, USD Billion, 2018 - 2030)

  • Web/Mobile
    • Audio/Text-based
    • Visualized
  • Call Centers

Telemedicine Facility Outlook (Revenue, USD Billion, 2018 - 2030)

  • Tele-hospital
  • Tele-home

Telemedicine End-use Outlook (Revenue, USD Billion, 2018 - 2030)

  • Providers
  • Payers
  • Patients
  • Others

Telemedicine Regional Outlook (Revenue, USD Billion, 2018 - 2030)

  • North Americ
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James

Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email:
sales@grandviewresearch.com
For More Information:
https://www.grandviewresearch.com

Biomarkers Industry Insights: Market Scope, Trends, and Strategic Opportunities

 


The global Biomarkers Market size is expected to reach USD 194.21 billion by 2030, registering a CAGR of 13.36% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising R&D investments by pharmaceutical and biotechnology companies, increasing number of Contract Research Organizations(CROs), and declining cost of clinical trials in emerging economies are the major driving factors for the industry. In addition, key players leverage various strategies to increase their production capabilities and promote the outreach of their product offerings. In June 2022, Paige announced its collaboration with Janssen to evaluate the potential of an (H&E)-based, (AI)-powered biomarker test, developed by Janssen, to screen for actionable FGFR3 and FGFR2 genomic alterations in patients with bladder cancer.

The increasing prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders is anticipated to fuel industry growth. According to the American Cancer Society, in 2022, an estimated 1.9 million new cancer cases were registered in the U.S., accounting for 609,360 deaths. Breast and lung cancers were observed as the most common ones worldwide. In addition, according to a report published in 2020 by the Institute for Health Metrics and Evaluation, cardiovascular diseases cause about 18.9 million deaths annually. Increasing research focused on the identification of new diagnostic biomarkers is fueling the industry's growth. For instance, in February 2022, Japanese scientists found two new diagnostic tissue biomarkers, PHGDH and TRIM29, indicated for malignant pleural mesothelioma.

These agents can be used to diagnose mesothelioma quickly and help doctors in differentiating between mesothelioma and other cancers. Moreover, in January 2020, a nascent research study published in the Journal of Nuclear Medicine discussed the potential of several breast cancer biomarkers. A notable and easily identifiable imaging biomarker recognized in the study was 18F-FDG PET. Moreover, the COVID-19 pandemic has encouraged the use of biomarkers for facilitating the detection & treatment of the disease. For instance, in March 2021, a new biomarker-based screening device, named Tiger Tech COVID Plus Monitor, was approved by the U.S. FDA.

The device can be used for the identification of biomarkers for COVID-19 and other hypercoagulable & hyperinflammatory conditions in individuals aged 5 years & above. Furthermore, various strategic initiatives undertaken by leading participants are anticipated to cater to demand. For instance, in August 2022, Roche received the U.S. FDA approval for VENTANA MMR RxDx Panel to detect pMMR endometrial cancer patients and dMMR solid tumor patients eligible for treatment with Merck’s immunotherapy Keytruda. This approval for the VENTANA MMR RxDx Panel is a label expansion of the company’s recent on-market panel. Also, in December 2021, Siemens Healthineers partnered with Freenome to identify novel suitable markers for the detection of early breast cancer to expand its existing imaging technologies.

Related Press Release@ Biomarkers Market Report

Biomarkers Market Report Highlights

  • The safety segment held the largest revenue share of 37.62% in 2023 owing to the increased adoption of safety biomarkers in drug discovery and development
  • The efficacy biomarkers segment is expected to grow at the fastest CAGR from 2024 to 2030 due to a rise in strategic collaborations for promoting research activities
  • The drug discovery & development segment dominated the market in 2023 due to the extensive R&D efforts taken by leading participants, and the rising adoption of biomarkers in drug discovery
  • The cancer segment led the market in 2023 and is expected to retain its dominance from 2024 to 2030. . However, the neurological diseases segment is anticipated to record the fastest CAGR over the forecast years
  • Asia Pacific is anticipated to attain the fastest CAGR from 2024 to 2030 due to the rising investments by key players and increasing disease prevalence in the region

Biomarkers Market Report Scope

Report Attribute

Details

Market size value in 2024

USD 91.52 billion

Revenue forecast in 2030

USD 194.21 billion

Growth rate

CAGR of 13.36% from 2023 to 2030

Historical data

2023

Actual data

2018 - 2022

Forecast period

2024 - 2030

 

Request For A Free Consultation @ https://www.grandviewresearch.com/request-free-consultation/70/rfc

Biomarkers Market Segmentation

Grand View Research has segmented the global biomarkers market on the basis of on type, product, application, disease, and region:

Biomarkers Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Safety Biomarkers
  • Efficacy Biomarkers
  • Predictive Biomarkers
  • Surrogate Biomarkers
  • Pharmacodynamic Biomarkers
  • Prognostics Biomarkers
  • Validation Biomarkers

Biomarkers Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Consumable
  • Services
  • Software

Biomarkers Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Diagnostics
  • Drug Discovery & Development
  • Personalized Medicine
  • Disease Risk Assessment
  • Others

Biomarkers Disease Outlook (Revenue, USD Million, 2018 - 2030)

  • Cancer
    • Safety Biomarkers
    • Efficacy Biomarkers
    • Predictive Biomarkers
    • Surrogate Biomarkers
    • Pharmacodynamic Biomarkers
    • Prognostics Biomarkers
    • Validation Biomarkers
  • Cardiovascular Diseases
    • Safety Biomarkers
    • Efficacy Biomarkers
    • Predictive Biomarkers
    • Surrogate Biomarkers
    • Pharmacodynamic Biomarkers
    • Prognostics Biomarkers
    • Validation Biomarkers
  • Neurological Diseases
    • Safety Biomarkers
    • Efficacy Biomarkers
    • Predictive Biomarkers
    • Surrogate Biomarkers
    • Pharmacodynamic Biomarkers
    • Prognostics Biomarkers
    • Validation Biomarkers
  • Immunological Diseases
    • Safety Biomarkers
    • Efficacy Biomarkers
    • Predictive Biomarkers
    • Surrogate Biomarkers
    • Pharmacodynamic Biomarkers
    • Prognostics Biomarkers
    • Validation Biomarkers
  • Others
    • Safety Biomarkers
    • Efficacy Biomarkers
    • Predictive Biomarkers
    • Surrogate Biomarkers
    • Pharmacodynamic Biomarkers
    • Prognostics Biomarkers
    • Validation Biomarkers

Biomarkers Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James

Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email:
sales@grandviewresearch.com
For More Information:
https://www.grandviewresearch.com

                   

 

Friday 14 June 2024

Clinical Trials Industry Insights: Market Scope, Trends, and Strategic Opportunities

 


The growing prevalence of chronic diseases and the incidence of novel diseases is expected to boost the clinical trials market. According to the World Heart Report 2023, over half a billion people worldwide are affected by Cardiovascular Diseases (CVDs), which caused over 20.5 million deaths in 2021. Furthermore, according to the Parkinson’s Foundation, approximately 1 million individuals in the U.S. currently suffer from Parkinson's Disease (PD), which is projected to increase to over 1.2 million by 2030.

The prevalence of rare or orphan diseases has garnered attention in recent years, necessitating specialized clinical trials. As diseases become more varied and complex, there is a heightened demand for specialized expertise in clinical trial design, patient recruitment, and data analysis. Trial sponsors seek experts capable of navigating the intricacies of diverse diseases. Thus, the aforementioned factors are expected to drive the market demand.

Request For Free Sample Report @ Clinical Trials Market Report

From Firsts to Finals: The Four Phases

·         Phase I: Phase I clinical trials are the first stage of human testing for a new medical intervention. They focus on evaluating its safety, determining the appropriate dosage, and collecting initial data on how the body interacts with the intervention.

·         Phase II: Phase II clinical trial is a controlled study conducted on a relatively larger group of patients to assess the safety and efficacy of a new medical intervention, such as a drug or treatment.

·         Phase III: A Phase III clinical trial involves a large-scale and rigorously controlled study conducted to confirm and further evaluate the safety and effectiveness of a medical intervention identified in Phase II.

·         Phase IV: A Phase IV clinical trial, also known as post-marketing surveillance, occurs after a medical product has received regulatory approval.

Top Trends Streamlining Clinical Trials:

·         Rising Demand for Personalized Medicine: Numerous companies are focusing on the development of targeted therapies to cater to specific genetic diseases. Clinical trials are pivotal in validating these therapies, potentially leading to smaller, more specialized markets. Furthermore, several regulatory authorities offer flexibility in trial designs, with real-world evidence and favorable regulatory pathways for smaller patient populations, positively influencing market growth.

·         Technological Advancements: The growing adoption of decentralized clinical trials and telemedicine in clinical trials offers several advantages, which are expected to drive the overall potential of the industry. Moreover, the integration of remote monitoring technology enables continuous patient data collection outside clinical settings. This real-time data improves trial accuracy, enhances patient engagement, and allows more comprehensive insights into patient health.

·         Research & Development Activities: Collaborations between biopharmaceutical companies and CROs are expected to impact the industry positively. Contract research organizations have seen a major boost owing to rising R&D expenditures and pharmaceutical companies’ increasing focus on cost containment. Several biopharmaceutical and medical device companies are outsourcing their clinical trials to CROs to reduce product development time and cost.

The Final Diagnosis:

Clinical trials might seem like an intricate world of complex processes but they are the bridge between ground-breaking discoveries and life-saving treatments. By participating in such trials, individuals can contribute to medical progress, thereby paving the way for a healthier future. Even the smallest contribution can help make a world of great difference!

Recent Developments

·         In August 2023, Parexel & Partex entered a strategic partnership aimed at utilizing Artificial Intelligence (AI)-driven solutions to expedite the process of drug discovery and development for biopharmaceutical clients globally. The collaboration aimed to reduce risks associated with the assets in their respective portfolios.

·         In August 2023, Novo Nordisk announced to acquire Inversago Pharma. This acquisition was part of Novo Nordisk's strategic efforts to develop new therapies targeting individuals with obesity, diabetes, and other significant metabolic diseases

·         In April 2022, Charles River Laboratories International, Inc. disclosed its acquisition of Explora BioLabs Holdings, Inc., a leading provider of contract vivarium research services.

 

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James

Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Friday 7 June 2024

Germany Legal Cannabis Market To Reach $85.6 Million By 2030

 


The Germany legal cannabis market size is expected to reach USD 85.6 million by 2030, growing a CAGR of 14.9% over the forecast period, according to a new report by Grand View Research, Inc. Factors such as rising social acceptance of cannabis, growing medical applications of cannabis, increasing R&D & technological innovation, and the introduction of new cultivation technologies are expected to drive the cannabis industry in the country. For instance, in February 2024, according to data published in Reuters, 4.5 million individuals are estimated to use cannabis in Germany.

Furthermore, favorable government initiatives and reimbursement policies fuel the market growth. For instance, according to data published by the Federal Union of German Associations of Pharmacists (ABDA), the number of prescriptions for medical cannabis for Statutory Health Insurance (SHI)-insured patients in Germany was 338,500 in 2022. Furthermore, according to the same source, 14,840 Kg of cannabis was delivered to pharmacies for medicinal purposes in 2022.

Moreover, growing awareness among people regarding the therapeutic applications of cannabis and the launch of online cannabis prescription platforms drive market growth. For instance, in September 2023, Cantourage Group SE, a Berlin-based company, introduced Telecan, a telemedicine platform for medical cannabis, under the guidance of Florian Wesemann, a medical doctor. The platform offers a simple and convenient way for potential patients to access cannabis therapy.

In recent years, there has been a significant rise in the usage of cannabis and its derivatives in Germany. The medical application of CBD has gained immense popularity, leading to the development of policies for its distribution and use by the government. Moreover, conferences and various events being organized for cannabis industry leaders drive market growth. For instance, the International Cannabis Business Conference was to be held in Berlin in April 2024, Germany’s biggest annual gathering of influential political and cannabis business leaders.

The cannabis industry has witnessed the development of new techniques and technologies that aid in its cultivation, and these advancements are expected to boost market growth. The demand for technologically advanced cannabis production has led to the optimization of resources by cultivators. This, coupled with the increased utilization of hemp and marijuana in various sectors, such as personal care & cosmetics, pharmaceuticals, nutraceuticals, and food, & beverages, has impelled market growth. In addition, the use of cannabis and its derivatives by various businesses as a raw material for manufacturing products is projected to drive market growth over the forecast period.

List of Key Players in the Germany Legal Cannabis Market

  • The Cronos Group
  • Organigram Holding, Inc
  • Tilray Brands, Inc
  • Canopy Growth Corporation
  • Aurora Cannabis
  • SynBiotic
  • Cansativa GmbH
  • DEMECAN
  • Four 20 Pharma
  • Avextra Pharma GmbH

Related Press Release@ Germany Legal Cannabis Market Report

Germany Legal Cannabis Market Report Highlights

  • By source, the hemp segment accounted for the largest revenue share in 2023 due to rising demand for hemp-derived CBD oil and its health benefits. Furthermore, food manufacturing processes use hemp seeds and oil, which propels market growth.
  • By derivatives,the CBD segment dominated the market with the largest revenue share in 2023, owing to the growing acceptance of CBD and its use in treating various chronic conditions.
  • By end-use, the industrial-use segment held the largest market share in 2023 owing to the growing demand for hemp products, including fiber, seed, stalks, hurds, and oils for various industries, such as food & beverage, personal care, and animal care.

Germany Legal Cannabis Market Report Scope

Report Attribute

Details

Market size value in 2024

USD 37.2 Million

Revenue forecast in 2030

USD 85.6 Million

Growth rate

CAGR of 14.9% from 2024 to 2030

Base year for estimation

2023

Actual data

2018 - 2023

Forecast data

2024 - 2030

Request For A Free Consultation@ https://www.grandviewresearch.com/request-free-consultation/457511/rfc

Germany Legal Cannabis Market Segmentation

Grand View Research has segmented the Germany legal cannabis market based on source, derivatives, and end-use:

Germany Legal Cannabis Source Outlook (Revenue, USD Million, 2018 - 2030)

  • Hemp
    • Hemp oil
    • Industrial Hemp
  • Marijuana
    • Flower
    • Oil and Tinctures

Germany Legal Cannabis Derivatives Outlook (Revenue, USD Million, 2018 - 2030)

  • CBD
  • THC
  • Others

Germany Legal Cannabis End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Industrial Use
  • Medical Use
    • Chronic Pain
    • Depression and Anxiety
    • Arthritis
    • Post-traumatic Stress Disorder (PTSD)
    • Cancer
    • Migraines
    • Epilepsy
    • Alzheimer’s
    • Multiple Sclerosis
    • AIDS
    • Amyotrophic Lateral Sclerosis
    • Tourette’s
    • Diabetes
    • Parkinson's
    • Glaucoma
    • Others
  • Recreational Use

Explore Horizon, the world's most expansive market research database

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James

Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email:
sales@grandviewresearch.com
For More Information:
https://www.grandviewresearch.com

AI In Patient Engagement Market Size is Predicted to Witness 21.2% CAGR till 2030

  The global  AI In Patient Engagement Market  size is expected to reach USD 23.1 billion by 2030 , registering a CAGR of 21.2% from 2024 to...